TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are diagnosed with AD in accordance with the criteria of the Japanese Dermatological Association~* Subjects whose AD affects 5% to 40% of BSA (excluding scalp) at the screening and baseline examinations~* Subjects who have an IGA score of 2 or 3 at the screening and baseline examinations~Exclusion Criteria:~-Subjects who have an AD or contact dermatitis flare-up defined as a rapid intensification of AD, within 28 days prior to the baseline examination

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 2 Years
- Healthy Volunteers: f

Study Arms:
- OPA-15406 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Correlation of Continuous Glucose Monitoring and Glucose Tolerance Testing With Pregnancy Outcomes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant patients~* Age 18-50~* Gestational age less than 28 weeks~Exclusion Criteria:~* Minors less than 18 years of age~* Multiple gestation~* Known fetal anomalies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Continuous Glucose Monitor in pregnancy (Type: OTHER): The Seven Continuous Glucose Monitoring System: Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female children 1-12 years of age~* Clinical or laboratory evidence of varicella zoster infection~* Patients suspected of having varicella zoster infection~Exclusion Criteria:~* Patients unable to swallow~* Concomitant use of probenecid~* Positive pregnancy~Additional protocol-defined inclusion/exclusion criterial may apply. For detailed information on eligibility, please contact the study center nearest to you (see below), or call the following number 1-862-778-3544 or 1-434-951-3228

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vortioxetine vs Sertraline in Mexicans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals had to be between 18 and 85 years of age~* Clinical diagnosis of type 2 diabetes mellitus based on the American Diabetes Association criteria,~* They had to receive anti-diabetic treatment, Clinical diagnosis of major depressive episode according Association Diagnostic and Statistical Manual of Mental Disorders, five edition (DSM-V)~* Ratings scale score ≥ 14 by means of Hamilton Depression scale (HAM-D)~* Patients had to give verbal and written informed consent for this study~Exclusion Criteria:~* Neurological illness~* Psychoactive medications~* Type I diabetes~* Active suicidal ideation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Vortioxetine therapy (Type: EXPERIMENTAL): patients who gave informed consent and met the inclusion criteria were attended by a psychiatrist. The pharmacological management were randomly assigned: these group of patients received vortioxetine (10 mg/day) for 8 weeks, in addition, the patients maintained their anti-diabetic treatment (oral hypoglycemic or insulin)
- Sertraline therapy (Type: EXPERIMENTAL): patients who gave informed consent and met the inclusion criteria were attended by a psychiatrist. The pharmacological management were randomly assigned: these group of patients received sertraline (75 mg / day) for 8 weeks, in addition, the patients maintained their anti-diabetic treatment (oral hypoglycemic or insulin)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of COVID-19 Convalescent Plasma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~Blood donors:~1. Age: \>18 and \<60 years~2. Body weight : \>55 kg~3. Confirmed previous SARS CoV-2 infection~4. Minimum 28 days after the last symptom or finishing of the isolation, or~5. 21 day without symptoms from the date of the negative SARS CoV-2 test~6. Written informed consent to participate in this clinical trial, to donate plasma and to store the specimen for future testing.~7. Concentration of COVID-19 IgG antibodies more than 5 AU/ml (Because measurement of neutralizing antibody titers is not available now, storing of retention sample from the convalescent plasma donation is performed for determining antibody titers at a later date)~8. Male donors, or female donors who have not been pregnant, or female donors who have been pregnant tested negative for HLA antibodies~9. Individuals who meet all regular voluntary donor eligibility requirements~Patients/recipients:~1. Age: \>18 years~2. Admitted to an acute care facility for the treatment of COVID-19 complications~3. Patients with severe or immediately life-threatening COVID-19, or~4. Patients who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.~5. Informed consent provided by the patient or healthcare proxy~Exclusion Criteria:~Blood donors:~1. Age : \<18 or \>60 years~2. Female subjects who are pregnant~3. HIV1,2 hepatitis B,C or syphilis infection~4. Donors ineligible for regular voluntary blood donation~Patients/recipients:~1. Age : \<18 years~2. Contraindication to transfusion (severe volume overload, history of anaphylaxis to blood products)~3. Patients who received in the past 30 days immunoglobulin therapy~4. Females who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Hospitalized patients with SARS CoV-2 infection (Type: OTHER): Hospitalized patients with SARS CoV-2 infection will receive an anti SARS-CoV-2 convalescent plasma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Applicants in methadone treatment may be eligible to participate in Phase 1 of the study.~* Applicants will be blind to the full details of the eligibility criteria.~* Unemployed~* Provided a urine sample at intake with a detectable concentration of cocaine metabolite or provided a cocaine positive sample during regular urinalysis testing at a methadone maintenance program~* Met DSM-IV criteria for cocaine dependence~* Were receiving welfare benefits in Baltimore, MD~* Received a score of less than or equal to 80% correct on a reading assessment~Exclusion Criteria~* Being at imminent risk for suicide~* Reported hallucinations~* Being incarcerated or otherwise under constant monitoring~* Earned less than or equal to $200 in unreported taxable income from legal activity in the previous month~* Having physical limitations that prevented typing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Employment Only (Type: ACTIVE_COMPARATOR): Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
- Contingency Management (Type: EXPERIMENTAL): Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy proven cases of breast cancer~Exclusion Criteria:~* Patients with onlybenign lesion~* Patients with onlyductal carcinomain situ (DCIS)~* Patients with recurrent/ residual breast cancer in same breast~* Pregnant women~* Lactating Women6.Patients with ferromagnetic or otherwise non-MRI compatible aneurysm clips.~* The presence of an implanted medical device that is not MRI-compatible, including, but not limited to: pacemaker, defibrillator~* Patients with contraindications for MRIdue to embedded foreign metallic objects. Bullets, shrapnel, metalwork fragments, or other metallic material adds unnecessary risk to the patient.~* Known history of severe claustrophobia~* Patients under the age of 18~* For patients with known history of allergic reaction to MR contrast material or abnormal kidney function (GFR \< 40 mL/ min), a contrast enhanced exam will not be performed; however, a non-contrast exam may be performed in these patients.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3D MR Fingerprinting scan (Type: EXPERIMENTAL): Three separate 3D MR fingerprinting scans: Before the start of chemotherapy, 7-10 days after the first cycle of chemotherapy, and within 1 month of the end of chemotherapy treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Participant provides written informed consent (participant, parent or legal guardian and, as appropriate, informed assent) to participate in the study before completing any study-related procedures.~2. Participant completed the TED-C14-006 or SHP633-301 studies (including participants in the standard of care treatment arms). Participants are considered to have completed SHP633-301 if they completed study assessments through week 24.~3. Participant understands and is willing and able to fully adhere to study requirements as defined in this protocol.~Exclusion Criteria:~1. There are no exclusion criteria for this study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care (SOC) treatment +/- teduglutide (TED) (Type: EXPERIMENTAL): Participants will receive 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injections once daily into 1 of the 4 quadrants of the abdomen or into either the thigh or arm as needed in addition to SOC treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntarily written informed consent~* Age: between 18 and 75 years (both inclusive).~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1. Cohort of patients with SCLC and endometrial cáncer ECOG PS ≤ 2.~* Life expectancy ≥ 3 months.~* Patients with a histologically/cytologically confirmed diagnosis of advanced disease of any of the following tumors:~  1. Breast cancer~ 2. Soft-tissue sarcoma~ 3. Primary bone sarcomas.~ 4. Gynecologic tumors (endometrial adenocarcinomas, epithelial ovarian cancer...)~ 5. Hepatocellular carcinoma~ 6. Gastroenteropancreatic neuroendocrine tumors~ 7. Small cell lung cancer (SCLC)~ 8. Gastric cancer~ 9. Bladder cancer~ 10. Adenocarcinoma of unknown primary site~* At least three weeks since the last anticancer therapy, including radiotherapy~* Adequate bone marrow, renal, hepatic, and metabolic function~* Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan within normal range (according to institutional standards).~* Women of childbearing potential must have a negative serum pregnancy test before study entry. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for six weeks after discontinuation of treatment~Exclusion Criteria:~* Concomitant diseases/conditions:~  * History or presence of unstable angina, myocardial infarction, congestive heart failure, or clinically significant valvular heart disease within last year.~ * Symptomatic or any uncontrolled arrhythmia~ * Ongoing chronic alcohol consumption, or cirrhosis~ * Active uncontrolled infection.~ * Known human immunodeficiency virus (HIV) infection.~ * Any other major illness that, in the Investigator's judgment~* Brain metastases or leptomeningeal disease involvement.~* Men or women of childbearing potential who are not using an effective method of contraception~* Patients who have had radiation therapy in more than 35% of the bone marrow. This criterion will not apply to cohort of patients with SCLC and endometrial cáncer.~* History of previous bone marrow and/or stem cell transplantation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- lurbinectedin (PM01183) / doxorubicin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Laser Lithotripsy During URS - Holmium vs Thulium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients planned for ureteroscopic treatment of ureteral and renal stones at the Day Surgery Unit at Haukeland University Hospital, Bergen, Norway~Exclusion Criteria:~* Known pathology of the upper urinary tract~* Untreated infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Holmium:YAG laser machine (Type: EXPERIMENTAL): The ureteral or renal stones planned for treatment with URS and laser lithotripsy are fragmented or dusted using a Holmium:YAG laser machine.
- Thulium Fiber laser machine (Type: EXPERIMENTAL): The ureteral or renal stones planned for treatment with URS and laser lithotripsy are fragmented or dusted using a Thulium Fiber laser machine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Innovation in the Treatment of Persistent Pain in Adults With NF1: Implementation of the iCanCope Mobile Application- Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adults 18+~* able to read and understand English at 5th grade level~* permanently reside in the United States~* have pain interference aggregate scores of three or more in the last two weeks using the Brief Pain Inventory-Short Form (BPI-SF) scale~Exclusion Criteria:~* have an undiagnosed case of NF1~* have documented major co-occurring psychiatric disease~* have moderate to severe cognitive deficits~* have depression assessed using the Patient Health Questionnaire (PHQ-9) or anxiety assessed using the Generalized Anxiety Disorder scale (GAD-7) greater than or equal to the appropriate thresholds (10=mild major depression; 5=mild severe anxiety)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- iCanCope (Type: EXPERIMENTAL): In this group, individuals will receive the iCanCope-NF program. The intervention will be delivered on a restricted password-protected mobile application. Participants will be encouraged to log onto the pain diary app (via automated alerts) once per day over the 8-week period to complete pain diary entries and develop and track their goals related to their pain, physical, social activities, sleep, as well as work through content based on their goals.
- iCanCop+Contingency Management (Type: EXPERIMENTAL): In addition to the iCanCope-NF activities outlined above, individuals will be rewarded with incentives (contingency management) such as points that are redeemable for prize-based gift card vouchers. Points will be accrued through access to new sections, daily check-ins, and engagement of the mobile application. Based on research, the total amount of money that can be earned by the patient over the course of the two months is 50 dollars USD.
- Control Group (Type: NO_INTERVENTION): The control group is designed to assess for potential effects on outcomes of time, attention, during the study. In addition to usual care, participants will be required to complete baseline and follow-up assessments similar to that of the intervention groups. They will be given that patient education, through preapproved flyers and information found from national websites regarding pain management, but no self-management strategies or opportunities for social support. They will not have access to the mobile application during the course of experiment; however, the control group will be offered the full iCanCope-NF program following the trial (T2) for a period of 2 months after the study is over.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult males and females~* Diagnosis of RRMS as defined by the revised (2005) McDonald Diagnostic Criteria for Multiple Sclerosis (MS).~* Signed inform consent prior to initiation of any study-mandated procedure.~Exclusion Criteria:~* A diagnosis of MS categorized as primary progressive or secondary progressive or progressive relapsing.~* Patients currently treated for an autoimmune disorder other than MS.~* Contraindications for MRI.~* Ongoing bacterial, viral, or fungal infection.~* History or presence of malignancy.~Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients' risk from participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- ACT-128800 Dose 1 (Type: EXPERIMENTAL): ACT-128800 Dose 1
- ACT-128800 Dose 2 (Type: EXPERIMENTAL): ACT-128800 Dose 2
- ACT-128800 Dose 3 (Type: EXPERIMENTAL): ACT-128800 Dose 3
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Anorexia Nervosa~* Women, age 30-70 years~* Osteoporosis or history of clinical fractures (spine, wrist, hip or ribs)~Exclusion Criteria:~* Diseases known to affect bone metabolism~* Hyperparathyroidism~* Medications known to affect bone metabolism in last 12 weeks (or bisphosphonate use in last 1 year)~* Pregnant and/or breastfeeding~* Diabetes mellitus~* History of malignancy involving or affecting the bone, any active malignancy, and/or radiation therapy to the bone~* Fractures of a bone other than a finger or toe in last 1 year

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Teriparatide (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete